Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Vertex Pharmaceuticals
So what: The trial showed that lung function improved more than 10% in patients with cystic fibrosis, exceeding expectations that analysts had put on the drug. This is a big step forward and sets the stage for the company to seek U.S. and European approval in the second half of 2011.
Now what: Analysts think that VX-770 could generate more than $500 million in sales, but that was before today's outstanding results. This Motley Fool Rule Breakers pick is truly breaking all the rules with this drug and if approved should lead to more gains for Vertex. I am bullish on the results and Vertex's solid pipeline of new drugs helping push the stock higher.
Interested in more info on Vertex Pharmaceuticals? Add it to your watchlist.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Vertex Pharmaceuticals is a Motley Fool Rule Breakers selection. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.